Meridian Bioscience, Inc.  

(Public, NASDAQ:VIVO)   Watch this stock  
Find more results for Meridian Bioscience, Inc
+0.02 (0.10%)
Real-time:   3:16PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.31 - 19.69
52 week 15.56 - 20.62
Open 19.63
Vol / Avg. 150,815.00/206,312.00
Mkt cap 825.54M
P/E 23.18
Div/yield 0.20/4.08
EPS 0.85
Shares 41.84M
Beta 1.19
Inst. own 93%
Jan 20, 2016
Q1 2016 Meridian Bioscience Inc Earnings Release (Estimated) Add to calendar
Nov 19, 2015
Meridian Bioscience Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 6, 2015
Q4 2015 Meridian Bioscience Inc Earnings Release
Sep 16, 2015
Meridian Bioscience Inc at Credit Suisse Small & Mid Cap Conference
Sep 10, 2015
Meridian Bioscience Inc at CL King Best Ideas Conference
Sep 9, 2015
Meridian Bioscience Inc at Robert W Baird and Co Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin 17.99% 18.24%
Operating margin 28.17% 28.77%
EBITD margin - 28.77%
Return on average assets - -
Return on average equity - -
Employees 550 -
CDP Score - -


3471 River Hills Dr
United States - Map
+1-513-2713700 (Phone)
+1-513-2713762 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Meridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Officers and directors

John A. Kraeutler Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Melissa A. Lueke Chief Financial Officer, Executive Vice President, Secretary
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Marco G. Calzavara President and Managing Director of Meridian Bioscience Europe
Age: 60
Bio & Compensation  - Reuters
Lawrence J. Baldini Executive Vice President - Operations and Information Systems
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard L. Eberly Executive Vice President; President of Meridian Life Science
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Vecheslav A. Elagin Ph.D. Executive Vice President - Research and Development
Age: 47
Bio & Compensation  - Reuters
Susan D. Rolih Executive Vice President - Regulatory & Quality Systems
Age: 65
Bio & Compensation  - Reuters
Michael C. Shaughnessy Executive Vice President; President of Meridian Diagnostics
Age: 58
Bio & Compensation  - Reuters
Marviette D. Johnson Vice President - Human Resources
Age: 46
Bio & Compensation  - Reuters
David C. Phillips Lead Independent Director
Age: 76
Bio & Compensation  - Reuters